NAFLD/NASH: Metabolic models characterization when dealing with the steatosis tissue abundancy

Fatty liver disease can manifest as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), which is often associated with progressive fibrosis leading to cirrhosis and hepatocellular carcinoma (HCC)1

By preserving the tissue microenvironment, ImaBiotech applies its multimodal histological, molecular and bioanalytical platforms for a simultaneous detection, localization and quantification of multiple endogenous biomarkers and exogenous pharmaceutical compounds without any labeling3–8. With our line of services (molecular and elemental imaging, laser capture microdissection, bioanalysis, multi-omics and data science), we can contribute to appropriately represent the biology and outcomes of human samples, when analyzing mouse models. (….)


Search news